Elevated depressive symptoms (DS) are associated with incident mild cognitive impairment and probable dementia in postmenopausal women. We examined the association of elevated DS with domain-specific cognitive changes and the moderating role of cardiovascular risk factor severity and cardiovascular disease (CVD). A total of 2221 elderly women who participated in the Women's Health Initiative Study of Cognitive Aging were separated into those with (N ¼ 204) and without (N ¼ 2017) elevated DS. The DS and multidomain cognitive outcomes were measured annually for an average follow-up of 5.04 years. Women with elevated DS showed baseline multidomain cognitive deficits but longitudinal declines in global cognition only. Persistent DS was related to greater global cognition, verbal knowledge and fluency, and memory declines. Significant DS-CVD interactions were observed cross-sectionally (but not longitudinally) for figural memory and fine motor speed. Future studies should investigate the role of nonvascular mechanisms linking DS and cognitive decline.
Introduction
Clinically significant depression occurs in 15% of the elderly patients and a significant majority of these individuals have milder depressive symptoms (DS) that fall short of the criteria for syndromal late-life depression (LLD). The number of elderly women having elevated DS is expected to increase exponentially in the coming decades. 1 Furthermore, the public health consequences of incident cognitive decline and Alzheimer disease (AD) are significantly greater for women than for men largely due to women's longer life expectancy. 2 Although LLD has been associated with an increased risk of incident cognitive decline and AD, 3 the effects of milder DS on future cognitive health are less clear. In the Women's Health Initiative Memory Study (WHIMS), elevated DS was associated with an increased risk of mild cognitive impairment (MCI) and probable dementia in those aged 65 years and older. 4 Late-life DS are also associated with longitudinal declines in psychomotor speed and executive functions in mixed gender studies [5] [6] [7] although the effects on episodic memory and nonmemory cognitive measures over time in elderly women remain elusive. Moreover, the differential effects of fluctuating and persistently elevated DS on domain-specific cognitive changes are poorly understood.
Of the prospective studies that have examined the longitudinal associations of late-life DS with domain-specific cognitive functions, most did not include a control group and/or measured cognitive functions at limited time points. 5, 6 Moreover, only a handful of investigations have examined the effects of persistent DS on the longitudinal cognitive performance and the findings vary. Although persistent DS was associated with only declines in information-processing speed in one study, symptom chronicity in patients with coronary heart disease was related to multidomain cognitive decline in another study. 5, 7 Additional investigations of the complex relationships between DS and longitudinal cognitive changes and the mechanisms that explain their associations in postmenopausal women are critically needed.
Vascular etiologies are hypothesized to play a critical role in linking depression and cognitive decline. [8] [9] [10] Late-life DS are often comorbid with cardiovascular risk factors (CVRFs) and cardiovascular and cerebrovascular disease. The coexistence of CVRFs and cardiovascular disease (CVD) with late-life DS is related to worse treatment outcomes and greater cognitive decline. 5, 11 Also, there is a bidirectional relationship between LLD and CVRF and vascular disease and these observations support the ''vascular depression'' hypothesis. 12, 13 Although emerging evidence indicates that worsening subclinical cerebrovascular disease in depressed elderly patients may be associated with future development of dementia, primarily of nonAlzheimer type, 10 others have not found an influence of vascular disease on late-life DS-cognitive impairment relationships. 14, 15 The CVRFs and CVD are also independently associated with an increased risk of cognitive decline and incident dementia. 16 The moderating role of CVRF severity and CVD on the relationship of DS with longitudinal changes in memory and nonmemory measures in elderly women remains poorly understood.
The data from a large, well-characterized cohort of postmenopausal women who participated in the Women's Health Initiative Study of Cognitive Aging (WHISCA) 17 were utilized here (1) to determine the relationship of DS and domainspecific cognitive changes and (2) to investigate the moderating effects of CVRF and CVD on various cognitive measures in those with DS, over a 7-year follow-up period.
Methods Participants
Women's Health Initiative Study of Cognitive Aging , an ancillary study to the Women's Health Initiative (WHI) randomized, placebo-controlled clinical trial of hormone therapy (HT) regimens based on conjugated equine estrogens, enrolled 2304 postmenopausal women between ages of 65 and 79 years from 14 of the 40 WHI clinical sites. The WHISCA assessments began an average of 3 years after the WHI's randomization to treatment. The study design, participant eligibility criteria, recruitment procedures, and principal findings of WHISCA have been previously published. [17] [18] [19] The National Institute of Health and the institutional review boards at the participating clinical centers approved WHISCA study protocols. All participants provided informed consent. The WHISCA participants who had completed at least the initial cognitive assessment and contributed complete data on baseline characteristics were included in this analysis (Table 1) . In addition, women who were free of MCI and probable dementia at WHISCA enrollment were included in this study. After excluding 83 women who did not meet the above-mentioned criteria, the final cross-sectional sample was comprised of a total of 2221 participants. Among the 2221 participants, 2123 women finished at least 1 follow-up assessment for the longitudinal analysis focused on change in cognitive performance from baseline.
Depressive Symptom Assessments
Depressive symptoms were assessed annually over up to 7 years using the 15-item Geriatric Depression Scale (GDS). 20, 21 A score of 5 or above at WHISCA initial assessment was considered as elevated DS. A cutoff point of 5 have been previously demonstrated as having excellent validity for detecting major depression in the elderly patients. 20, 22, 23 Additionally, women were classified based on the presence or absence of elevated DS at WHISCA year 1 follow-up: participants were considered to have persistently elevated DS if they scored positive (ie, !5 on GDS) at both WHISCA first (ie, enrollment) and second (ie, year 1) visits; fluctuating DS if they scored positive at only 1 visit; and no DS if they scored negative (ie, <5 on GDS) at both visits. This analysis cohort consisted of 2046 women who returned 1 year later for follow-up assessment.
Cardiovascular Risk Factor Score and CVD
We calculated the CVRF score closest to WHISCA baseline using the model described previously. 24 Briefly, age, systolic blood pressure, use of antihypertensive treatment, current smoking history, history of diabetes mellitus, and body mass index (BMI) were included in this nonlaboratory-based CVRF model that has been previously shown to predict CV events as accurately as risk factor indices based on laboratory-based values. 25 Women with a history of CVD at WHISCA baseline assessment and those having missing variables required for the CVRF score calculation were excluded from this analysis. Therefore, the final cohort for this analysis comprised 1820 women. The CVRF score ranged from 0.03 to 0.80.
History of CVD was defined as a self-report of myocardial infarction, coronary bypass surgery, angioplasty, congestive heart failure, angina, carotid endarterectomy/angioplasty, cardiac catheterization, aortic aneurysm, atrial fibrillation, or cardiac arrest at WHI baseline or occurrence of the incident events between WHI baseline and WHISCA enrollment. These incident events, including myocardial infarction, angina, congestive heart failure, coronary revascularization, carotid artery disease, coronary heart disease, and peripheral artery disease, were ascertained through central adjudication.
Domain-Specific Cognitive Assessments
Detailed cognitive assessments occurred annually at each WHISCA visit. 17 The 
Covariates
Demographic information, medical history, and lifestyle variables (including smoking and alcohol use) were obtained by self-report and clinical measurements using standardized study forms as detailed elsewhere. 17, 19 Current use of antidepressant medications was obtained through a medication inventory conducted at clinic visits. The HT assignment was based on whether women were randomized to intervention arms or the 353 (18) 34 (17) .76 Cardiovascular disease, n (%) 304 (15) 35 (17) .43 Stroke or TIA, n (%) 89 (4) 9 (4) 1.00 Prior hysterectomy, n (%) 761 (38) 92 (45) .04 Current use of antidepressant medications, n (%)
129 (6) 26 (13) <.001 Prior hormone therapy, n (%)
918 (46) 
Statistical Analysis
Women classified with and without elevated DS at WHISCA enrollment were compared with respect to demographic, lifestyle, cognitive, and clinical characteristics with chi-square tests and t-tests. Eight cognitive domains (global function, verbal knowledge, verbal fluency, figural memory, verbal memory, attention/ working memory, spatial ability, and fine motor speed) were assessed. Individual scores on each outcome measure were first standardized by dividing their difference from the cohort-wide mean at WHISCA enrollment by their standard deviation (SD). For cognitive domains based on more than 1 outcome measure, the standardized scores of these outcomes were averaged and renormalized. Scores from the BVRT were subtracted from 0 so that higher scores signified better performance, consistent with scores for other domains. The analysis focused on assessing 3 features of the data: (1) whether there was a difference in cognitive function scores associated with DS at WHISCA enrollment (cross-sectional), (2) whether such a difference persisted over follow-up (longitudinal pattern or average scores over time), and (3) whether the magnitude of the difference changed over time (longitudinal change from baseline). Additional modeling was carried out to examine the relationship of persistent and fluctuating levels of DS with domain-specific cognitive changes over time, with and without omitting 81 women who developed MCI or probable dementia during follow-up. This analysis was based on women who had a cognitive assessment at 1-year follow-up in addition to enrollment, permitting classification into 3 groups: women without elevated DS at either time point, with fluctuating DS, and with persistently elevated DS.
Analysis of covariance (ANCOVA) was used for crosssectional comparisons. A mixed-model repeated measures ANCOVA incorporating within-person correlation was employed to assess whether mean cognitive domain scores and changes from WHISCA initial assessment in scores varied between women with and without DS. We assessed the significance of interaction terms between DS and prior CVD and between DS and CVRF score to explore whether the effects of DS on cognitive domain scores were moderated by either of these 2 factors. Models included adjustment for potential confounders (age, race/ethnicity, education, marital status, hysterectomy, antidepressant use, prior HT use, smoking, use of cholesterol-lowering medication, alcohol use, BMI, hypertension, diabetes, prior CVD including TIA or stroke, physical activity, and treatment arm). The baseline score for each cognitive domain was included as a covariate for the change from baseline in the longitudinal analysis. Because these analyses were exploratory and the cognitive variables are intercorrelated, type I error was not controlled for multiple outcomes. P < .01 was considered significant.
Statistical analyses were performed with SAS statistical software, version 9.2 (SAS Institute Inc, Cary, North Carolina).
Results
Of the 2221 participants, 204 (9.2%) women met criteria for elevated DS at WHISCA baseline. Women with elevated DS were more likely to be African American, have lower education, endorse a history of hysterectomy, diabetes mellitus, past alcohol use, be obese, report being on antidepressants, and less likely to be physically active (Table 1) . Among the 155 women reporting antidepressant use at baseline, 71 (46%) were taking selective serotonin reuptake inhibitors (DS: 8.3%; no DS: n ¼ 2.7%); 61 (39%) were taking tricyclic antidepressants (DS: n ¼ 2.5%; no DS: n ¼ 2.8%); and 23 (15%) were taking other classes or were on combination therapy (DS: n ¼ 1.96%; no DS: n ¼ 0.9%). Women with elevated DS at baseline had significantly lower raw scores on all cognitive measures except fine motor speed ( Figure 1 summarizes the mean covariate-adjusted decline in cognitive domain test scores associated with elevated DS (relative to no symptoms) based on the cross-sectional and longitudinal analyses, with the differences averaged across time for the overall longitudinal pattern as well as for the changes from baseline. Elevated DS were associated with lower mean baseline scores in domains including verbal knowledge and verbal memory (P < .01), figural memory (P < .001), and visuospatial abilities (P < .0001). The overall longitudinal pattern also showed lower scores for women with elevated DS: most significant differences were noted for global cognition, verbal knowledge, figural memory, and visuospatial abilities (P < .001), followed by verbal memory (P < .01). In terms of change from baseline, global cognitive function (P < .01) declined over time in women with elevated DS.
We performed additional analyses to examine the relationship of persistent and fluctuating levels of elevated DS with domain-specific cognitive changes over time. Women were classified into those without elevated DS at either time point (N ¼ 1752), with fluctuating DS (N ¼ 202), and with persistently elevated DS (N ¼ 92). Mean GDS scores for these groups at baseline were 0.86, 3.90, and 7.32, respectively. At baseline, the fluctuating DS group was more likely to have lower education, be physically inactive, endorse a history of past drinking, and be on antidepressants, whereas the persistent DS group was more likely to have lower education, poorer 3MS scores and diabetes, endorse current smoking and past drinking histories, be nonwhite, physically inactive, and on antidepressants, relative to controls (P < .01).
After full covariate adjustment, women with persistently elevated DS showed greater longitudinal declines in global cognition, verbal knowledge, and verbal fluency (P < .01) and a trend in figural memory (P < .05), whereas fluctuating DS course showed no changes (Figure 2 ). After excluding women who developed MCI/probable dementia (N ¼ 81) during follow-up, the persistent DS group findings slightly diminished but remained significant, whereas the fluctuating DS group results enhanced slightly. The above-mentioned results remained essentially unchanged after we repeated the longitudinal analyses controlling for the mean length of follow-up time since baseline.
Moderating Effects of CVRF and CVD on DS-Cognitive Change Relationships
We found significant interactions at WHISCA baseline between DS and CVD on figural memory and fine motor speed (P < .01), where women with CVD and DS performed worse than each of the other 3 groups (Table 3) . However, no interactive effects of DS with CVD and CVRF scores on the longitudinal cognitive changes were observed. Since the CVRF model used here did not include cholesterol status, we conducted additional analyses and found no significant DS-high cholesterol interactions on multiple-domain cognitive function (P > .05).
Discussion
Although elevated DS were cross-sectionally associated with multidomain cognitive deficits, significant associations with longitudinal declines were only observed for global cognition in a cohort of community-dwelling postmenopausal women free of pathological cognitive impairment at baseline. However, women with persistently elevated DS showed greater declines in global cognition and nonmemory measures and a trend in episodic memory measures whereas those with fluctuating DS course had no changes during follow-up. The CVD and CVRF severity histories did not moderate the longitudinal DS-cognitive change relationships. Elderly women with elevated DS performed poorly on several memory and nonmemory cognitive domains at baseline and longitudinal patterns over time. Our observations in this well-characterized sample of elderly women with elevated DS largely mirror findings reported in those with syndromal LLD. 26 Nondemented acutely depressed older adults who perform poorly in memory and executive function measures at baseline may have coexisting MCI and be at higher risk of developing dementia at follow-up, when compared to those with acute LLD who remain cognitively normal over time. [27] [28] [29] Our findings suggest that DS, regardless of the severity, frequently coexist with cognitive deficits that do not meet the criteria for MCI and probable dementia although the consequence of this comorbidity is unclear.
The present study findings that elevated DS are related to declines in global cognition measure are consistent with some 7, 30 but not all studies. 31 The inconsistencies in findings may be due to the fact that the DS-cognitive decline associations reported previously are largely driven by the course of depressive symptomatology. Our observations of persistent DS being associated with nonmemory declines over time are in accordance with previous mid-and late-life studies. 7, 32 The vulnerability to the effects of elevated DS on executive function measures appears to be greatest with symptom chronicity and advanced age. 7 Elevated DS is likely to persist over time in some older adults and the risk of developing major depression is significantly higher at follow-up. 33 Persistence of LLD is associated with multiple-domain cognitive deficits at baseline, suggesting that the presence of baseline cognitive impairment may be prognostic indicators of LLD outcomes. 11, [34] [35] [36] We extend these prior observations to a cohort of postmenopausal women with milder DS, suggesting that both subclinical and syndromal DS, if persistent, can increase the risk of future cognitive decline.
Our observations that fluctuating levels of DS do not detrimentally affect multiple cognitive measures are consistent with the literature. 30 On the contrary, remission of DS and syndromal depression has been associated with MCI and probable dementia among elderly women and in mixed-gender studies. 27, 37 The fluctuating DS course is likely reflective of symptom remission due to the changes in psychosocial stressors, physical ailments, and/or remission of depression. We are unable to disentangle the association of these factors with the changes in DS status in this study.
The observations that the CVRF and CVD histories did not detrimentally alter cognitive measures over time in women with DS underscore the complexities in the pathophysiological mechanisms linking DS with subsequent cognitive decline. Although our results are also consistent with some studies, 14, 15 detrimental effects on cognition when depression coexists with certain CVRFs have been previously reported. For instance, the relationship of depression with incident cognitive impairment was affected by diabetes in a previous study. 38 Executive dysfunction is associated with orbitofrontal volume loss in diabetic patients with depression. 39 Higher CVRF scores have also been shown to predict lesser recovery of working memory deficits and executive dysfunction to the treatment of LLD.
11 Persistent DS in patients with coronary heart disease may increase the risk of future cognitive decline. 5 The DS chronicity after acute coronary syndrome may be associated with decreased white matter integrity in the anterior cingulate although these findings were no longer significant after controlling for CVRFs. 40 Although we did not find an interactive relationship of DS with CVRF and CVD scores on cognitive decline, a few points are worthy of mention. First, the smaller sample size in the persistent DS group precluded us from examining the effects of CVRFs and CVD when comorbid with chronic DS on cognition. Second, we did not examine the interactive relationship of DS and individual vascular risk factors separately rather calculated the CVRF score for each individual using an all-inclusive model. Therefore, it is still possible that late-life DS, especially when chronic and occurring in those with specific vascular risk factors (eg, in diabetics) and coronary heart disease, may result in accelerated declines in different cognitive domains. This should be the focus of future investigations.
The lack of influence of CVRF score severity and CVD on the DS-associated memory decline also suggests that this relationship may be mediated by medial temporal lobe neurodegeneration and nonvascular etiologies. The LLD is associated with hippocampal volume loss from excessive stress-related glucocorticoid release. 41 Also, amyloid and neurofibrillary tangles, genetic heritability, proinflammatory cytokines, and oxidative stress have been implicated in the mechanistic underpinnings of both LLD and AD. 9, [42] [43] [44] [45] Since DS in the elderly population is a heterogeneous syndrome, future studies that examine the association of DS with incident cognitive impairment should carefully delineate older adults with depression into subtypes based on comorbidity and neuropsychological deficits.
The strengths of this study include the well-characterized cohort of high-functioning, healthy elderly women, the large sample size, the availability of annual domain-specific cognitive measurements, and the ability to adjust for multiple potential confounders. However, several limitations need to be addressed. First, since we relied on self-reported GDS scores to define DS, it is possible that some women may have met major depressive disorder criteria on a structured clinical interview. Regardless, the mean GDS scores even in women who had persistent DS were in the milder range and therefore, the vast majority of women with positive scores had subclinical DS. Second, we are unable to comment on the effects of the age of onset, current episode duration, and number of prior episodes on our study findings. Recent evidence suggests that later onset depression may be a prodromal manifestation of AD, whereas recurrent DS with onset in mid-life may increase the risk of vascular dementia. 46 Third, persistent and fluctuating levels of DS were defined based on only 2 GDS measures similar to prior studies. 5 We primarily took this approach due to missing GDS measurements at follow-up and to prevent sample size attrition. Fourth, antidepressant use was associated with attention/working memory, figural memory, and fine motor speed (P < .05) at baseline. Although we controlled for baseline antidepressant use, we did not include follow-up medication data in our analyses. Future studies should define persistence and fluctuations of DS based on the measurements at multiple time points and also factor in the effects of followup antidepressant use history on the DS-cognitive health relationships. Fifth, the sample size in the persistently elevated DS group is relatively small and may have influenced our findings. Sixth, the CVRFs and CVD history was ascertained by selfreport, which may have resulted in inaccurate estimation and misclassification of these conditions and may have reduced the strength when examining for interactions. Seventh, our sample is not population based and included women who participated in a HT trial, which limit the generalizability of our findings. Finally, since this study was largely exploratory, adjustments were not carried out for multiple comparisons.
In conclusion, persistent DS course resulted in greater declines affecting multiple cognitive domains in our elderly women cohort. The CVRF and CVD histories do not appear to influence the association of DS with cognitive decline. A differential course of managing DS in an attempt to reduce the risk of cognitive decline may not be warranted for women with CVRFs and CVD. Future prospective studies should confirm our findings and determine whether treatment of DS will reverse cognitive deficits in those women with different degrees of CVRF and CVD severity.
